ClinicalTrials.gg

Program

SHR-1139

A development code. Also written as “SHR-1139 Injection”, “SHR-1139 and SHR-1139 pleacebo” and “The SHR-1139 injection”.

In Jiangsu HengRui Medicine's pipeline, IL23p19/ IL36R. Its studies are mostly in Psoriasis · Colitis, Ulcerative · Pyoderma Gangrenosum, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Mar 9, 20258 company-led studies, 7 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine87 open or runningphase 2since Mar 9, 2025Mar 9, 2025Dec 31, 2026phase 2 · NCT07719530
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1139, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2025First study: phase 2 study in Moderate to Severe Plaque PsoriasisFirst studyNCT06875934 · 145 enrolled · China
  2. Jun 26, 2025Phase 1 study in Moderate to Severe Plaque PsoriasisNCT07051538 · 64 enrolled · China
  3. Jul 13, 2025Phase 1 study in PsoriasisNCT07078695 · 24 enrolled · Australia
  4. Nov 14, 2025Phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07232576 · 21 enrolled · China
  5. Feb 26, 2026Phase 2 study in Pyoderma GangrenosumNCT07444684 · 20 planned · China
  6. Jul 17, 20262 phase 2 studiesNCT07719530, NCT07758075
  7. Oct 30, 2026Phase 2 study in Palmoplantar Pustulosis of AdultsNCT07923851 · 40 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in PsoriasisNCT07719530
  2. Jun 2027Primary completion: phase 2 study in Pyoderma GangrenosumNCT07444684
  3. Jul 2027Primary completion: phase 2 study in Plaque PsoriasisNCT07758075
  4. Aug 2027Primary completion: phase 2 study in Adult Patients With Moderately to Severely Active Ulcerative ColitisNCT07232576

TargetBeta

“IL23p19/ IL36R”the company's pipeline, read by Claude · source

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923851Palmoplantar Pustulosis of Adults · China2Not yet recruitingNov 202740
NCT07758075Plaque Psoriasis · China2Not yet recruitingJul 202750
NCT07719530Psoriasis · China2RecruitingDec 31, 202660
NCT07444684Pyoderma Gangrenosum · China2Not yet recruitingJun 202720
NCT07232576Adult Patients With Moderately to Severely Active Ulcerative Colitis · China2Active, not recruitingAug 202721
NCT07078695Psoriasis · Australia1Active, not recruitingSep 30, 202624
NCT07051538Moderate to Severe Plaque Psoriasis · China1CompletedNov 28, 202564
NCT06875934Moderate to Severe Plaque Psoriasis · China2Active, not recruitingNov 2025145

How it is read

Names in the registry

  • “SHR-1139 Injection”, 6 entries
  • “SHR-1139 and SHR-1139 pleacebo”, 2 entries
  • “The SHR-1139 injection”, 1 entry
  • “SHR-1139”, 1 entry
  • “SHR-1139 intravenous injection.”, 1 entry

Codes read as this program: SHR1139.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.